Please sign in to follow a disease.
Chromosome 17 disorder
MONDO:0020583Chromosomal disorder in which chromosome 17 is affected.
Also known as: chromosome 17 abnormality
29 clinical trials for this condition and its sub-types, 0 tagged with Chromosome 17 disorder itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Chromosome 17 disorder
-
Partial duplication of chromosome 17 0 trials · 19 incl. sub-types
2 sub-types
- Partial duplication of the short arm of chromosome 17 0 trials · 18 incl. sub-types Sub-types →
- Partial duplication of the long arm of chromosome 17 0 trials · 1 incl. sub-types Sub-types →
-
Partial deletion of chromosome 17 0 trials · 12 incl. sub-types
2 sub-types
- Chromosome 17p deletion 6 trials · 11 incl. sub-types Sub-types →
- Partial deletion of the long arm of chromosome 17 0 trials · 1 incl. sub-types Sub-types →
-
Mosaic trisomy 17 0 trials
-
Ring chromosome 17 0 trials
Most studied deeper sub-types
-
Tailored Three-Drug combo targets Myeloma's toughest genetic weak spot
Disease control OngoingResearchers are testing whether a combination of daratumumab, pomalidomide and dexamethasone can help people whose multiple myeloma has come back and carries a genetic change called del(17p). This change, found in about 10% of patients at diagnosis, makes the cancer harder to tre…
Phase 2 • Sponsor: Fondazione EMN Italy Onlus • Aim: Disease control
Last updated Sep 11, 2026 00:00 UTC
-
New hope for Tough-to-Treat blood cancers: targeted pill shows promise
Disease control OngoingThis phase 2 trial tests the drug venetoclax (a pill) in 110 people with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study includes two groups: those with a specific genetic change (17p deletion) and those who have failed oth…
Phase 2 • Sponsor: AbbVie • Aim: Disease control
Last updated Aug 21, 2026 00:00 UTC
-
Can a One-Time gene injection halt nerve damage in CMT1A?
Disease control CancelledThis trial tests a one-time gene therapy injection for people with Charcot-Marie-Tooth disease type 1A (CMT1A), a genetic nerve disorder that causes progressive muscle weakness. The therapy delivers a gene that produces a protein to support nerve health. Three adults aged 18 to 3…
Phase 1/2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New program aims to ease burden on families of kids with rare diseases
Symptom relief By invitation onlyThis study tests a program called FACE-Rare, designed to support family caregivers of children with rare, life-limiting diseases. The program includes three sessions to help families prepare for future medical decisions and improve their quality of life. Researchers will compare …
Sponsor: Children's National Research Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Zapped nerves: study planned to boost recovery after surgery — but never started
Knowledge-focused CancelledThis study was designed to see if giving a short, mild electrical stimulation to compressed nerves during surgery could speed up recovery of strength and function. It planned to include people with nerve compression in the spine or limbs who were already scheduled for decompressi…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC